Import from '@womanrx/ui'

Retatrutide Storage, Stability & Shelf Life: What Every Woman Needs to Know

What Is Retatrutide and How Does It Work?

Retatrutide is a single synthetic peptide that simultaneously activates three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). No approved drug currently combines all three in one molecule. This triple agonism is the reason the Phase 2 NEJM trial by Jastreboff et al. reported a mean body-weight reduction of 24.2% at 48 weeks in the 12 mg group, a figure exceeding anything previously published for a non-surgical intervention at that time.

Each receptor plays a distinct metabolic role.

GLP-1 Receptor Agonism

GLP-1R activation slows gastric emptying, increases glucose-dependent insulin secretion, and reduces appetite through hypothalamic signaling. This is the same receptor targeted by semaglutide and liraglutide. Women with polycystic ovary syndrome (PCOS) often have blunted GLP-1 responses after meals, which is one reason GLP-1-based therapies show particular metabolic utility in this population.

GIP Receptor Agonism

GIPR co-agonism amplifies insulin release and may directly reduce food intake through central pathways. The GIPR is also expressed in adipose tissue and bone, which carries implications for bone turnover. Women approaching menopause already face accelerated bone loss, and the interaction between GIPR activation and bone metabolism in perimenopausal and postmenopausal women is an area where direct evidence in women remains thin.

Glucagon Receptor Agonism

The GCGR component drives hepatic glucose output and, critically for weight loss, increases energy expenditure through thermogenic effects in brown adipose tissue. This third mechanism differentiates retatrutide from dual agonists like tirzepatide. It also means caloric expenditure goes up even without exercise, which matters for women with mobility limitations, postpartum fatigue, or menopausal fatigue syndromes.

Retatrutide's Chemical Structure and Why It Affects Storage

Retatrutide is a synthetic acylated peptide, meaning it is a chain of amino acids with a long fatty-acid side chain attached. That fatty-acid tail allows it to bind albumin in the bloodstream, extending its half-life to approximately six days and enabling once-weekly dosing. Peptide-based drugs with fatty-acid acylation are inherently sensitive to three environmental factors: temperature, light, and physical agitation.

Understanding the chemistry helps you understand why storage instructions are not optional.

Temperature Sensitivity

Peptide bonds can hydrolyze when exposed to temperatures outside the acceptable range. Heat above 30°C accelerates this breakdown, producing degradation products that are pharmacologically inactive and, in some cases, immunogenic. Freezing is equally damaging: ice crystal formation physically disrupts the peptide's tertiary structure and can cause the fatty-acid tail to dissociate from the peptide backbone, producing aggregates that will not re-dissolve on thawing.

The GLP-1 analog drug class, which shares the acylated peptide structure with retatrutide, requires refrigeration at 2°C to 8°C as a class standard. Retatrutide-specific stability data from Eli Lilly's Phase 2 trial supply chain have not yet been published in a peer-reviewed journal, but the structural analogy to semaglutide and tirzepatide makes the 2°C to 8°C requirement the clinically appropriate assumption.

Light and UV Exposure

The aromatic amino acids in retatrutide's sequence, particularly phenylalanine and tyrosine, absorb UV radiation. Prolonged light exposure generates reactive oxygen species that oxidize those residues, shortening the molecule and reducing receptor-binding affinity. Store the pen or vial in the original carton at all times when not in use.

Physical Agitation

Shaking or dropping a prefilled pen can cause protein aggregation. Aggregates look like cloudiness or visible particles. If you see either, discard the pen. Do not attempt to re-dissolve it by warming.

Proper Storage: A Room-by-Room Guide for Women

Storage conditions are not always straightforward for women whose daily routines involve multiple locations, travel, or temperature-controlled environments affected by hormonal fluctuations (yes, perimenopausal hot flashes can raise ambient bedroom temperature enough to matter over weeks of storage).

At Home: Refrigerator Storage

Keep unused pens in the main body of your refrigerator, not the door shelf. Door shelves experience the largest temperature swings with repeated opening. The target range is 2°C to 8°C (36°F to 46°F). A small refrigerator thermometer costs under ten dollars and confirms your fridge maintains this range, particularly relevant if your refrigerator is older.

Do not store retatrutide near the freezer compartment or against the back wall of the fridge, where surface temperatures can dip below 0°C even with the thermostat set correctly.

In-Use Pens: Room-Temperature Window

Once a pen has been removed from the refrigerator, it may be stored at room temperature below 30°C (86°F). For the approved GLP-1 analog class, this window is up to 28 days. Retatrutide-specific data confirming or modifying this window are not yet available from a published FDA submission, and the 28-day figure should be treated as a class-level estimate until Eli Lilly publishes formal stability data in the context of an NDA filing.

After 28 days at room temperature, discard the pen even if medication remains.

Travel and Transit

Air travel presents two specific risks. First, the cargo hold of a commercial aircraft can reach temperatures well below 0°C during cruise altitude. Never check retatrutide in luggage. Carry it on your person or in a carry-on bag with an insulated travel case containing a gel ice pack (not dry ice, which can freeze the pen).

Second, airport security X-ray machines do not affect peptide drugs. You do not need a medical exemption from the X-ray conveyor. Heat from scanners is not generated.

For road trips, the glove compartment of a car parked in summer sun can reach 65°C to 80°C. Use an insulated case.

A practical framework for women traveling with retatrutide, developed from aggregated GLP-1 analog handling guidance and real-world logistics:

| Travel Scenario | Recommended Action | |---|---| | Flight under 4 hours | Insulated pouch, gel ice pack, carry-on only | | Flight over 4 hours | Medical-grade travel cooler (e.g., FRIO or equivalent) | | Road trip, summer | Insulated bag in passenger cabin, not glove box or trunk | | Hotel stay | Request mini-fridge; confirm 2-8°C with travel thermometer | | Camping or outdoor event | Avoid; plan injection timing before departure |

Shelf Life and Expiration Dates

Pharmaceutical expiration dates on peptide injectables are determined through real-time stability studies conducted by the manufacturer under ICH Q1A(R2) guidelines. Eli Lilly has not yet published retatrutide-specific expiration data because the drug has not received FDA approval as of early 2025. In the Phase 2 supply chain for the Jastreboff et al. Trial, drug was supplied under GMP conditions with investigational expiry dates assigned by Eli Lilly's internal stability program.

For comparator context: semaglutide injection (Ozempic) carries a refrigerated shelf life of approximately 2 years from manufacture and a 56-day in-use period at room temperature. Tirzepatide (Mounjaro) carries a refrigerated shelf life up to 21 months. Retatrutide's shelf life under approved conditions will likely fall in a similar range given its structural similarity, but this is extrapolation, not confirmed data.

Always use the expiration date printed on the carton. Do not use a pen past its expiration date even if the solution appears clear.

How Women's Physiology Intersects With Retatrutide Dosing and Handling

Menstrual Cycle Effects on GI Side Effects

GLP-1 receptor agonists commonly cause nausea, particularly early in dose escalation. Progesterone, which peaks in the luteal phase (days 15-28 of a typical cycle), already slows gastric motility. Combining high progesterone with GLP-1-mediated gastric slowing may intensify nausea in the two weeks before your period. Gastric emptying rate varies across the menstrual cycle, and this is a real physiological consideration, not a coincidence.

Timing your weekly injection to fall in the follicular phase rather than the late luteal phase may reduce nausea severity. This is worth discussing with your prescriber. Keep the injection day consistent each week, but if you are starting a new escalation step, starting it right after your period ends is a reasonable approach.

PCOS and Metabolic Overlap

Women with PCOS have insulin resistance, elevated androgens, and often impaired GLP-1 secretion. Triple agonism through GLP-1R, GIPR, and GCGR addresses multiple metabolic defects at once and may be particularly beneficial in this population. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism confirmed GLP-1 agonists reduce weight, insulin resistance, and androgen levels in women with PCOS, and retatrutide's broader mechanism of action could produce additive effects not yet formally studied in this group.

Perimenopause and Menopause

Perimenopausal women experience estrogen fluctuations that impair insulin sensitivity and shift fat distribution toward visceral adiposity. Visceral fat is more metabolically active and more responsive to GLP-1-based therapies than subcutaneous fat. The GCGR-mediated thermogenic component of retatrutide may provide additional benefit in postmenopausal women, who have lower resting metabolic rates partly due to loss of estrogen's anabolic and thermogenic effects.

Postmenopausal bone health is a separate concern. GCGR activation has been shown in preclinical studies to reduce bone mineral density through increased osteoclast activity. Direct human data in postmenopausal women on retatrutide are not yet available. Women in this life stage should discuss baseline DEXA scanning and calcium and vitamin D optimization before starting this drug class.

Postpartum and Lactation

Retatrutide is not currently approved, and no lactation transfer data exist in humans. Based on its molecular weight (approximately 4,970 Da after acylation) and high plasma protein binding, transfer into breast milk is expected to be low. However, low transfer does not equal zero risk, and no safety threshold has been established for an infant. Women who are breastfeeding should not use retatrutide until human lactation data are available.

Pregnancy and Contraception: A Required Conversation

Retatrutide is contraindicated in pregnancy. This is not an ambiguous precaution.

GLP-1 receptor agonists as a class have shown embryo-fetal toxicity in rodent studies at clinically relevant exposures. The FDA pregnancy category system has been replaced by the Pregnancy and Lactation Labeling Rule (PLLR), but the mechanistic concern remains: GLP-1 receptors are expressed in the placenta and fetal tissues, and activation during organogenesis carries theoretical teratogenic risk. Retatrutide adds GCGR agonism, and glucagon signaling also plays a role in fetal metabolic programming, amplifying the concern beyond a single-receptor effect.

The Jastreboff Phase 2 trial required participants to use reliable contraception and excluded anyone who was pregnant or planning to become pregnant within the trial period. This is standard for investigational obesity drugs with reproductive toxicity signals.

What "Reliable Contraception" Means in This Context

For women of reproductive age taking retatrutide (or any investigational drug with reproductive toxicity), reliable contraception means a method with a failure rate below 1% per year with typical use. Options include:

• Combined oral contraceptive pills (noting that GLP-1-mediated changes in gastric emptying may theoretically reduce absorption of oral medications, though this has not been formally quantified for retatrutide)
• Intrauterine devices (hormonal or copper)
• Subdermal implant
• Tubal ligation or partner vasectomy

If you use oral contraceptives and start retatrutide, discuss with your prescriber whether a backup method is warranted during dose escalation, when nausea and vomiting are most likely to interfere with pill absorption. This concern applies as a precaution rather than a confirmed pharmacokinetic interaction.

If You Become Pregnant While on Retatrutide

Stop the drug immediately. Contact your OB-GYN. Retatrutide's half-life of approximately six days means it will clear your system within four to five weeks after the last dose, but early embryonic development is most vulnerable in the first eight weeks of gestation. Report the exposure to Eli Lilly's pregnancy pharmacovigilance registry, which will exist once the drug is approved. Until then, report to the FDA MedWatch system at fda.gov.

Planning a Pregnancy After Retatrutide

Based on the six-day half-life, five half-lives (roughly 30 days) is the minimum washout period before conception attempts. Some clinical teams recommend waiting three to six months to allow full metabolic stabilization, weight plateau, and nutritional repletion before conception, consistent with guidance used for bariatric surgery patients. ACOG has not yet issued specific guidance on GLP-1 washout before conception, but the bariatric analogy is the current clinical reference point.

Who Is Right for Retatrutide (and Who Is Not)

Because retatrutide is investigational as of early 2025, access is currently limited to clinical trials. Based on the Phase 2 eligibility criteria and the drug's mechanism, here is a life-stage breakdown.

Women Who May Be Candidates in Future Clinical Practice

• Adult women with obesity (BMI >30) or overweight (BMI >27) with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, PCOS, sleep apnea)
• Perimenopausal and postmenopausal women with visceral obesity who have not responded adequately to GLP-1 monotherapy
• Women with PCOS and significant insulin resistance who need broader metabolic action than a GLP-1 alone provides
• Women who have reached a weight-loss plateau on tirzepatide or semaglutide

Women Who Are Not Appropriate Candidates

• Pregnant women or those planning pregnancy within the washout period
• Breastfeeding women (insufficient safety data)
• Women with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (GCGR and GLP-1R agonism share this class concern)
• Women with a history of pancreatitis (class-level caution)
• Women with severe osteoporosis who have not had a formal bone-health assessment, given preclinical GCGR and bone data

Recognizing Degraded Drug: What to Look For Before Each Injection

Each time you use a retatrutide pen, inspect the solution. It should be clear, colorless to slightly yellow, and free of particles. Discard and replace the pen if you see:

• Cloudiness or milkiness
• Visible floating particles
• Color that has shifted to brown or orange
• Any crystalline material inside the cartridge

Do not shake the pen to try to clear any of these findings. Aggregated peptide does not re-dissolve safely.

Disposal: Sharps and Unused Medication

Unused or expired retatrutide pens should not be flushed or thrown in household trash. Use an FDA-cleared sharps disposal container for used needles. For unused drug, locate a pharmaceutical take-back program through the DEA's authorized collector search at deadiversion.usdoj.gov or your local pharmacy's return program.

Women with children at home: lock all injectable medications in a dedicated medication lock box. Children have been harmed by accidental exposure to GLP-1 class drugs.

Evidence Gap: What We Do Not Yet Know

Honesty about evidence gaps is part of good clinical communication. Several specific gaps exist for women:

• Retatrutide-specific stability data have not been published outside of Eli Lilly's internal GMP files. All specific temperature and shelf-life figures applied to retatrutide in clinical practice currently extrapolate from the broader acylated-peptide GLP-1 analog class.
• Women-specific PK data from the Phase 2 trial have not been separately reported. In the published Jastreboff et al. Results, sex-disaggregated weight-loss and pharmacokinetic data were not featured in the primary publication.
• Bone mineral density outcomes in women on retatrutide were not reported as a primary or secondary endpoint in Phase 2. This is a meaningful gap for perimenopausal and postmenopausal participants.
• Lactation transfer studies do not exist. This is standard for investigational drugs but leaves a real clinical void.
• Oral contraceptive interaction pharmacokinetics have not been studied with retatrutide specifically, though data from semaglutide suggest no clinically significant reduction in oral contraceptive exposure.

The Phase 3 program, which Eli Lilly has initiated, will likely address some of these gaps, particularly through longer-duration safety endpoints and broader demographic subgroup reporting.